Xenon Pharmaceuticals (NASDAQ:XENE) Share Price Crosses Above 50-Day Moving Average – Here’s Why

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) crossed above its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $41.91 and traded as high as $42.17. Xenon Pharmaceuticals shares last traded at $42.10, with a volume of 1,253,476 shares changing hands.

Recent Xenon Pharmaceuticals Headlines

These are some of the XENE headlines that stood out recently:

• Neutral Sentiment: HC Wainwright retained its Buy rating on Xenon, offering a counterpoint to the lower forecasts. MarketBeat coverage
• Negative Sentiment: The analyst lowered projected EPS for Q4 2026 to ($1.14) and for 2027 to ($4.90) for the full year, with quarterly estimates of ($1.22) for Q2 and ($1.25) for Q4. The revisions point to slightly deeper expected losses. MarketBeat coverage
• Negative Sentiment: Longer-range forecasts were also reduced: EPS estimates moved to ($4.07) for 2028, ($2.25) for 2029 and ($0.44) for 2030. The largest revision was for 2030, from a prior estimate of ($0.18), suggesting profitability may take longer to reach. MarketBeat coverage

Analysts Set New Price Targets

Several research firms have recently commented on XENE. Royal Bank Of Canada decreased their target price on shares of Xenon Pharmaceuticals from $81.00 to $70.00 and set an “outperform” rating for the company in a research report on Friday, September 18th. Robert W. Baird dropped their price target on shares of Xenon Pharmaceuticals from $97.00 to $90.00 and set an “outperform” rating on the stock in a research report on Friday, September 18th. Jefferies Financial Group restated a “buy” rating and issued a $90.00 target price on shares of Xenon Pharmaceuticals in a report on Monday, September 28th. Deutsche Bank cut Xenon Pharmaceuticals from a “buy” rating to a “hold” rating and cut their target price for the company from $90.00 to $46.00 in a research report on Friday, September 18th. Finally, Wall Street Zen downgraded Xenon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Sunday, October 11th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $71.31.

Xenon Pharmaceuticals Stock Down 1.2%

The business has a 50 day moving average price of $41.13 and a two-hundred day moving average price of $52.13.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings results on Monday, November 9th. The biopharmaceutical company reported ($1.11) EPS for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.02. As a group, research analysts forecast that Xenon Pharmaceuticals Inc. will post -4.62 earnings per share for the current fiscal year.

Insider Buying and Selling at Xenon Pharmaceuticals

In related news, insider Christopher Kenney sold 7,068 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $60.25, for a total value of $425,847.00. Following the sale, the insider owned 2 shares of the company’s stock, valued at approximately $120.50. The trade was a 99.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Thomas Patrick Kelly acquired 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 30th. The stock was purchased at an average price of $37.32 per share, for a total transaction of $559,800.00. Following the purchase, the chief financial officer owned 15,000 shares of the company’s stock, valued at $559,800. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 2.91% of the company’s stock.

Institutional Trading of Xenon Pharmaceuticals

Large investors have recently bought and sold shares of the company. HighVista Strategies LLC grew its stake in shares of Xenon Pharmaceuticals by 100.8% during the 3rd quarter. HighVista Strategies LLC now owns 70,908 shares of the biopharmaceutical company’s stock worth $2,637,000 after acquiring an additional 35,590 shares during the period. First Trust Advisors LP increased its holdings in Xenon Pharmaceuticals by 17.8% in the 3rd quarter. First Trust Advisors LP now owns 10,377 shares of the biopharmaceutical company’s stock worth $386,000 after acquiring an additional 1,566 shares during the last quarter. Cibc World Market Inc. increased its holdings in Xenon Pharmaceuticals by 3.4% in the 3rd quarter. Cibc World Market Inc. now owns 20,632 shares of the biopharmaceutical company’s stock worth $767,000 after acquiring an additional 672 shares during the last quarter. Diversified Trust Co raised its stake in Xenon Pharmaceuticals by 4.9% in the 3rd quarter. Diversified Trust Co now owns 41,160 shares of the biopharmaceutical company’s stock valued at $1,531,000 after acquiring an additional 1,938 shares during the period. Finally, Russell Investments Group Ltd. raised its stake in Xenon Pharmaceuticals by 29.3% in the 3rd quarter. Russell Investments Group Ltd. now owns 198,100 shares of the biopharmaceutical company’s stock valued at $7,373,000 after acquiring an additional 44,873 shares during the period. 95.45% of the stock is owned by hedge funds and other institutional investors.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for neurological disorders. The company’s research emphasizes ion channels, proteins that help regulate the electrical activity of nerve cells. Its lead program is azetukalner, formerly known as XEN1101, an oral Kv7 potassium-channel opener being developed for seizure disorders, including focal epilepsy. Xenon is also advancing other drug candidates aimed at neurological conditions. Founded in 1996, Xenon is headquartered in Burnaby, British Columbia, and conducts drug development activities in North America.